Ischemic stroke market research report: by diagnosis (CT, MRI, carotid ultrasound, cerebral angiography), drug class (tissue plasminogen activator, anticoagulant, antiplatelet, antihypertensive), surgery, end user – Global forecast till 2027
ID: MRFR/MED/3980-HCR | February 2021 | Region: Global | 120 pages
Market Scenario:
Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain. The underlying condition of this type of obstruction is the development of fat deposits lining the vessel walls, which is known as atherosclerosis. According to the World Health Organization (WHO), stroke accounts for around 17 million deaths annually. As per the Centers for Disease Control and Prevention (CDC), stroke leads to 1 out of every 20 deaths costing around USD 34 billion each year in the U.S. Higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.
The key strategies adopted by leading industry players incldues new product launches and collaborations. For instance, in April 2016, the novel TransCarotid Artery Revascularization (TCAR) procedure launched by Silk Road Medical, Inc, received FDA approval. This minimally invasive technique is designed to access the common carotid artery. Moreover, in March, 2015, WATCHMAN, a closure device designed to prevent stroke in patients with atrial fibrillation received FDA approval.
Rising cases of ischemia stroke are driving the demand for surgical procedures in stroke treatment. Increasing demand for minimally invasive procedures and advancements in surgical procedures are the key factors boosting the growth of the global ischemic stroke market. High cost of the surgical procedures and excessive usage of medication for the treatment of ischemic stroke are hindering the market growth.
The global market for ischemic stroke is expected to grow at a CAGR of approximately 8.3% during the forecast period 2017-2023.
Research Methodology:
Sources: Annual reports, Press release, White paper, and Company presentation
Intended Audience:
- Ischemic Stroke Drug Suppliers
- Ischemic Stroke Drug Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Segmentation:
The ischemic stroke is segmented on the basis of diagnosis, drug class, surgery and end-users.
On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others.
On the basis of the drug class, the market is segmented into tissue plasminogen activator, anticoagulant, antiplatelet, antihypertensive, and others
On the basis of the surgery, the market is segmented into carotid endarterectomy, angioplasty, and endovascular mechanical thrombectomy
On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.
Regional Analysis:
The global ischemic stroke market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.
The Americas has emerged as the largest market for the global ischemic stroke owing to the favorable government initiatives, technological innovations, and increasing demand for ischemic stroke products. According to the American Heart Association, ischemic stroke is among the top three causes of death in the U.S. and Canada, nearly 795,000 patients suffering from strokes are treated in the 2014.
Europe is the second largest global ischemic stroke market owing to the advancements in the surgical devices technology along with the rising occurrence of acute ischemia stroke cases among the patients. In the European Union, over 31 million people are living with diabetes aged between 20 and 79. This signifies an average diabetes prevalence rate of 8.6% of the adult population. Some other factors driving the market includes the growing percentage of diabetes mellitus population mainly in the developed countries of Europe
Asia Pacific is anticipated to unfold as the most promising market for the global ischemic stroke owing to increasing prevalence of stroke cases in this region. China and India are considered as a big market for ischemic stroke within the forecast period. Manufacturers are expanding their operations in Asia Pacific region as these regions hold immense potential for the market growth.
The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.
Key Players:
The emergence of new and cost-effective medication options for the treatment of ischemic stroke could open up new opportunities to the new players in the global ischemic stroke market. Additionally, emerging markets, such as India and China, could also open new opportunities to new players.
Some of key the players in the Americas ischemic stroke market are Abbott Laboratories (U.S.), Medtronic plc (U.S.), Boston Scientific Corporation (U.S.), Cordis Corporation (U.S.), Koninklijke Philips N.V. (Netherland), GE Healthcare (U.S.), Stryker Corporation (U.S.), Genentech, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Boehringer Ingelheim (Germany), Sanofi (France), Covidien plc (Ireland), Philips Healthcare (U.S.), Johnson & Johnson (U.S.), Penumbra, Inc. (U.S.), GE Healthcare (U.S.), Siemens Healthcare (U.S.), Hitachi, Ltd (Japan), Biogen (U.S.), Daiichi Sankyo (U.S.), Pfizer Inc. (U.S.), and others
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Surgery Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 7. Global Ischemic Stroke Market, By Diagnosis
7.1 Introduction
7.2 Computed Tomography (CT)
7.3.1 Market Estimates & Forecast, 2020 – 2027
7.3 Magnetic Resonance Imaging (MRI)
7.3.1 Market Estimates & Forecast, 2020 – 2027
7.4 Carotid Ultrasound
7.4.1 Market Estimates & Forecast, 2020 – 2027
7.5 Cerebral Angiography
7.5.1 Market Estimates & Forecast, 2020 – 2027
7.6 Electrocardiography
7.7.1 Market Estimates & Forecast, 2020 – 2027
7.8 Echocardiography
7.8.1 Market Estimates & Forecast, 2020 – 2027
7.4 Others
Chapter 8. Global Ischemic Stroke Market, By Drug Class
8.1 Introduction
8.2 Tissue Plasminogen Activator
8.2.1 Market Estimates & Forecast, 2020 – 2027
8.3 Anticoagulant
8.3.1 Market Estimates & Forecast, 2020 – 2027
8.4 Antiplatelet
8.4.1 Market Estimates & Forecast, 2020 – 2027
8.5 Antihypertensive
8.5.1 Market Estimates & Forecast, 2020 – 2027
8.6 Others
Chapter 9. Global Ischemic Stroke Market, By Surgery
9.1 Introduction
9.2 Carotid Endarterectomy
9.2.1 Market Estimates & Forecast, 2020 – 2027
9.3 Angioplasty
9.3.1 Market Estimates & Forecast, 2020 – 2027
9.4 Endovascular Mechanical Thrombectomy
9.4.1 Market Estimates & Forecast, 2020 – 2027
Chapter 10. Global Ischemic Stroke Market, By End User
10.1 Introduction
10.2 Hospitals & Clinics
10.2.1 Market Estimates & Forecast, 2020 – 2027
10.3 Medical Institutes
10.3.1 Market Estimates & Forecast, 2020 – 2027
10.4 Research Organization
10.4.1 Market Estimates & Forecast, 2020 – 2027
10.5 Others
10.5.1 Market Estimates & Forecast, 2020 – 2027
Chapter. 11 Global Ischemic Stroke Market, By Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 Italy
11.3.1.4 Spain
11.3.1.5 U.K
11.3.1.6 Rest Of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 Republic Of Korea
11.4.6 Rest Of Asia Pacific
11.5 The Middle East & Africa
11.5.1 United Arab Emirates
11.5.2 Saudi Arabia
11.5.3 Rest Of The Middle East & Africa
Chapter 12 Company Landscape
12.1 Introduction
12.2 Market Share Analysis
12.3 Key Development & Strategies
12.3.1 Key Developments
Chapter 13 Company Profiles
13.1 Abbott Laboratories
13.1.1 Company Overview
13.1.2 Drug Class Overview
13.1.3 Financials
13.1.4 SWOT Analysis
13.2 Medtronic Plc
13.2.1 Company Overview
13.2.2 Drug Class Overview
13.2.3 Financial Overview
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.3 Boston Scientific Corporation
13.3.1 Company Overview
13.3.2 Drug Class Overview
13.3.3 Financial Overview
13.3.4 Key Development
13.3.5 SWOT Analysis
13.4 Cordis Corporation
13.4.1 Company Overview
13.4.2 Drug Class/Business Segment Overview
13.4.3 Financial Overview
13.4.4 Key Development
13.4.5 SWOT Analysis
13.5 Merck & Co., Inc.
13.5.1 Company Overview
13.5.2 Drug Class Overview
13.5.3 Financial Overview
13.5.4 Key Developments
13.6 Koninklijke Philips N.V.
13.6.1 Company Overview
13.6.2 Drug Class Overview
13.6.3 Financial Overview
13.6.4 Key Developments
13.7 GE Healthcare
13.7.1 Overview
13.7.2 Drug Class Overview
13.7.3 Financials
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.8 Stryker Corporation
13.8.1 Company Overview
13.8.2 Drug Class/Business Segment Overview
13.8.3 Financial Overview
13.8.4 Key Development
13.8.5 SWOT Analysis
13.9 Pfizer Inc.
13.9.1 Company Overview
13.9.2 Drug Class Overview
13.9.3 Financial Overview
13.9.4 Key Developments
13.10 Others
Chapter 14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO’s View Point
14.1.2 Unmet Needs Of The Market
14.2 Key Companies To Watch
14.3 Prediction Of Pharmaceutical Industry
Chapter 15 Appendix
LIST OF TABLES
Table 1 Ischemic Stroke Industry Synopsis, 2020 – 2027
Table 2 Ischemic Stroke Market Estimates And Forecast, 2020 – 2027, (USD Million)
Table 3 Ischemic Stroke Market By Region, 2020 – 2027, (USD Million)
Table 4 Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)
Table 5 Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)
Table 6 Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)
Table 7 Ischemic Stroke Market By End Users, 2020 – 2027, (USD Million)
Table 8 North America Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)
Table 9 North America Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)
Table 10 North America Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)
Table 11 North America Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)
Table 12 US Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)
Table 13 US Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)
Table 14 US Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)
Table 15 US Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)
Table 16 Canada Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)
Table 17 Canada Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)
Table 18 Canada Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)
Table 19 Canada Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)
Table 20 South America Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)
Table 21 South America Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)
Table 22 South America Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)
Table 23 South America Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)
Table 24 Europe Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)
Table 25 Europe Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)
Table 26 Europe Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)
Table 27 Europe Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)
Table 28 Western Europe Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)
Table 29 Western Europe Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)
Table 30 Western Europe Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)
Table 31 Western Europe Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)
Table 32 Eastern Europe Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)
Table 33 Eastern Europe Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)
Table 34 Eastern Europe Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)
Table 35 Eastern Europe Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)
Table 36 Asia Pacific Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)
Table 37 Asia Pacific Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)
Table 38 Asia Pacific Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)
Table 39 Asia Pacific Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)
Table 40 The Middle East & Africa Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)
Table 41 The Middle East & Africa Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)
Table 42 The Middle East & Africa Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)
Table 43 The Middle East & Africa Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation For Ischemic Stroke Market
Figure 3 Segmentation Market Dynamics For Ischemic Stroke Market
Figure 4 Global Ischemic Stroke Market Share, By Diagnosis 2020
Figure 6 Global Ischemic Stroke Market Share, By Drug Class 2020
Figure 7 Global Ischemic Stroke Market Share, By Surgery, 2020
Figure 8 Global Ischemic Stroke Market Share, By End Users, 2020
Figure 9 Global Ischemic Stroke Market Share, By Region, 2020
Figure 10 North America Ischemic Stroke Market Share, By Country, 2020
Figure 11 Europe Ischemic Stroke Market Share, By Country, 2020
Figure 12 Asia Pacific Ischemic Stroke Market Share, By Country, 2020
Figure 13 The Middle East & Africa Ischemic Stroke Market Share, By Country, 2020
Figure 14 Global Ischemic Stroke Market: Company Share Analysis, 2020 (%)
Figure 15 Abbott Laboratories: Key Financials
Figure 16 Abbott Laboratories: Segmental Revenue
Figure 17 Abbott Laboratories: Geographical Revenue
Figure 18 Medtronic Plc: Key Financials
Figure 19 Medtronic Plc: Segmental Revenue
Figure 20 Medtronic Plc: Geographical Revenue
Figure 21 Boston Scientific Corporation: Key Financials
Figure 22 Boston Scientific Corporation: Segmental Revenue
Figure 23 Boston Scientific Corporation: Geographical Revenue
Figure 24 Cordis Corporation: Key Financials
Figure 25 Cordis Corporation: Segmental Revenue
Figure 26 Cordis Corporation: Geographical Revenue
Figure 27 Merck & Co., Inc.: Key Financials
Figure 28 Merck & Co., Inc.: Segmental Revenue
Figure 29 Merck & Co., Inc.: Geographical Revenue
Figure 30 Koninklijke Philips N.V.: Key Financials
Figure 31 Koninklijke Philips N.V.: Segmental Revenue
Figure 32 Koninklijke Philips N.V.: Geographical Revenue
Figure 33 GE Healthcare: Key Financials
Figure 34 GE Healthcare: Segmental Revenue
Figure 35 GE Healthcare: Geographical Revenue
Figure 36 Stryker Corporation: Key Financials
Figure 37 Stryker Corporation: Segmental Revenue
Figure 38 Stryker Corporation: Geographical Revenue
Figure 39 Pfizer Inc.: Key Financials
Figure 40 Pfizer Inc.: Segmental Revenue
Figure 41 Pfizer Inc.: Geographical Revenue
Bottom of Form